PPCB · Propanc Biopharma, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“It is management's opinion that these conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of at least twelve months from the issue date of this Quarterly Report.”View the 10-Q filed May 14, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on May 18, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on May 18, 2026.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PPCB
this stock
Propanc Biopharma, Inc.
|
$2.10M | — | — | — | 14.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.64B | +14.6% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.46B | +2.8% | +20.8% | 19.4 | 2.5% |
|
ARGX
Argenx SE
|
$61.87B | +17.8% | — | — | 2.0% |
|
CSLLY
Csl Ltd
|
$58.97B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 2.1%
- Net QoQ
- +29.4K sh
- Top holder
- JANE STREET GROUP, LLC
Performance
Raw-price comparisons begin at the captured split on May 18, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PPCB | -15.8% | -30.3% | — | -37.0% | — |
| SPY | -1.2% | -2.0% | +16.1% | -0.8% | +11.6% |
| vs SPY | -14.6% | -28.3% | — | -36.2% | — |